Sobrerol

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Summary

Sobrerol is a mucolytic indicated in patients with chronic respiratory diseases.

Generic Name
Sobrerol
DrugBank Accession Number
DB13315
Background

Not Available

Type
Small Molecule
Groups
Experimental
Structure
Weight
Average: 170.252
Monoisotopic: 170.13067982
Chemical Formula
C10H18O2
Synonyms
Not Available

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Associated Conditions
Indication TypeIndicationCombined Product DetailsApproval LevelAge GroupPatient CharacteristicsDose Form
Used in combination for symptomatic treatment ofFebrile respiratory illnessCombination Product in combination with: Acetaminophen (DB00316)••• ••••••••••••••• •••••• ••••••
For therapyRespiratory disorders••••••••••••••••••••••••••• ••••••••
For therapyRespiratory disorders•••••••••••••••••••• ••• ••••••••• •••••• •••••••••••
Associated Therapies
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
MUCOFLUX 100mg capsulesCapsuleOralMYLAN HEALTHCARE SDN. BHD.2020-09-08Not applicableMalaysia flag
MUCOFLUX 80mg/10ml syrupSyrupOralMYLAN HEALTHCARE SDN. BHD.2020-09-08Not applicableMalaysia flag
มิวโคฟลักซ์Syrup40 mg/5mlOralบริษัท เมด้า ฟาม่าร์ (ประเทศไทย) จำกัด2012-01-25Not applicableThailand flag
มิวโคฟลักซ์Capsule100 mgOralบริษัท เมด้า ฟาม่าร์ (ประเทศไทย) จำกัด2012-01-25Not applicableThailand flag

Categories

ATC Codes
R05CB07 — Sobrerol
Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as menthane monoterpenoids. These are monoterpenoids with a structure based on the o-, m-, or p-menthane backbone. P-menthane consists of the cyclohexane ring with a methyl group and a (2-methyl)-propyl group at the 1 and 4 ring position, respectively. The o- and m- menthanes are much rarer, and presumably arise by alkyl migration of p-menthanes.
Kingdom
Organic compounds
Super Class
Lipids and lipid-like molecules
Class
Prenol lipids
Sub Class
Monoterpenoids
Direct Parent
Menthane monoterpenoids
Alternative Parents
Monocyclic monoterpenoids / Tertiary alcohols / Secondary alcohols / Hydrocarbon derivatives
Substituents
Alcohol / Aliphatic homomonocyclic compound / Hydrocarbon derivative / Monocyclic monoterpenoid / Organic oxygen compound / Organooxygen compound / P-menthane monoterpenoid / Secondary alcohol / Tertiary alcohol
Molecular Framework
Aliphatic homomonocyclic compounds
External Descriptors
Not Available
Affected organisms
Not Available

Chemical Identifiers

UNII
AI0NX02O35
CAS number
42370-41-2
InChI Key
OMDMTHRBGUBUCO-BDAKNGLRSA-N
InChI
InChI=1S/C10H18O2/c1-7-4-5-8(6-9(7)11)10(2,3)12/h4,8-9,11-12H,5-6H2,1-3H3/t8-,9+/m1/s1
IUPAC Name
(1S,5R)-5-(2-hydroxypropan-2-yl)-2-methylcyclohex-2-en-1-ol
SMILES
CC1=CC[C@H](C[C@@H]1O)C(C)(C)O

References

General References
  1. FDA Thailand Product Information: Mucoflex (sobrerol) oral syrup [Link]
  2. AIFA Package Leaflet: SOPULMIN (Sobrerol) intramuscular injection [Link]
ChemSpider
746841
RxNav
36669
ChEMBL
CHEMBL2374961
ZINC
ZINC000000407097
Wikipedia
Sobrerol

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
CapsuleOral
Granule
Granule300 MG
Injection, solutionIntramuscular
Solution / dropsOral
SprayRespiratory (inhalation)40 MG/3ML
SuppositoryRectal100 MG
SuppositoryRectal20 MG
SuppositoryRectal200 MG
SyrupOral
Granule, for solutionOral300 MG
SuppositoryRectal
SyrupOral
TabletOral
CapsuleOral100 mg
SyrupOral40 mg/5ml
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility26.0 mg/mLALOGPS
logP1.54ALOGPS
logP0.94Chemaxon
logS-0.82ALOGPS
pKa (Strongest Acidic)14.48Chemaxon
pKa (Strongest Basic)-2.8Chemaxon
Physiological Charge0Chemaxon
Hydrogen Acceptor Count2Chemaxon
Hydrogen Donor Count2Chemaxon
Polar Surface Area40.46 Å2Chemaxon
Rotatable Bond Count1Chemaxon
Refractivity49.98 m3·mol-1Chemaxon
Polarizability19.58 Å3Chemaxon
Number of Rings1Chemaxon
Bioavailability1Chemaxon
Rule of FiveYesChemaxon
Ghose FilterYesChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleNoChemaxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSsplash10-0zfu-9300000000-df2133dd98164dcd6984
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-000i-1900000000-949debf034a40ad213d9
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSsplash10-0f89-0900000000-db60ed94784ba582e165
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSsplash10-014i-0900000000-4a1b800096b1f800929e
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-0006-9300000000-06d284affa10c9871e19
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSsplash10-000f-9500000000-0f7ea1d1b37818a0bd30
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-0k96-9100000000-c89e3ada8b454d9f3161
Predicted 1H NMR Spectrum1D NMRNot Applicable
Predicted 13C NMR Spectrum1D NMRNot Applicable
Chromatographic Properties
Collision Cross Sections (CCS)
AdductCCS Value (Å2)Source typeSource
[M-H]-141.0360316
predicted
DarkChem Lite v0.1.0
[M-H]-143.35823
predicted
DeepCCS 1.0 (2019)
[M+H]+142.7818316
predicted
DarkChem Lite v0.1.0
[M+H]+145.7538
predicted
DeepCCS 1.0 (2019)
[M+Na]+141.0403316
predicted
DarkChem Lite v0.1.0
[M+Na]+151.6663
predicted
DeepCCS 1.0 (2019)

Drug created at June 23, 2017 20:39 / Updated at June 02, 2021 20:04